Syngene International Limited has received a significant favorable outcome in its ongoing tax litigation matters, securing a refund of ₹43.15 crores including interest for Assessment Year 2016-17. The biotechnology services company disclosed this development to stock exchanges following receipt of an order from tax authorities.

Tax Order Details and Timeline

The company received an order which gives effect to decisions made by the National Faceless Appeal Centre (NFAC) for Assessment Year 2016-17. This order was communicated to Syngene from the Deputy Commissioner of Income-tax, Circle 6(1)(1), Bangalore.

Background of Tax Litigation

The tax matter has a complex history spanning multiple assessment years. Initially, the Assessing Officer had passed an order under Section 143(3) making certain disallowances and additions, resulting in a demand of ₹72.34 crores. Syngene filed an appeal against these disallowances and additions.

The company also filed a Writ Petition before the Karnataka High Court regarding the adjustment of refunds granted for Assessment Years 2010-11 and 2011-12 against outstanding demands for other years, along with the non-issue of refund for AY 2012-13, aggregating to ₹48.91 crores.

Court Orders and Resolution Process

Syngene has provided updates on recent developments in this matter. The Karnataka High Court allowed the company's Writ Petition, while the NFAC partially allowed the company's appeal for AY 2016-17. Out of the total amount of ₹48.91 crores involved in the writ petition, ₹22.70 crores had been adjusted to AY 2016-17.

Financial Impact and Company Position

Syngene believes there will be no material impact on the company's financials, operations, or activities due to this development. The company expects a decrease in contingent liability related to Assessment Year 2016-17. The refund amount of ₹43.15 crores is yet to be received by the company.

The current order imposes no penalty, restrictions, or sanctions. The company stated it is analyzing the order and will take appropriate action as needed. This resolution represents a positive outcome for Syngene International in its ongoing tax litigation matters, providing clarity on a significant portion of its tax disputes.

Syngene International Limited has announced a comprehensive leadership restructuring that will see significant changes in its top management positions starting in 2026. The Board of Directors, following recommendations from the Nomination and Remuneration Committee, has approved multiple key appointments and role transitions that will shape the company's future direction.

Leadership Transition Details

The most notable change involves Ms. Kiran Mazumdar Shaw's elevation from Non-Executive Chairperson to Executive Chairperson, marking her transition to a Key Managerial Personnel role. This appointment will be effective from April 01, 2026, for a period of five years, subject to shareholder approval.

Executive Appointments and Departures

Mr. Peter Bains will step down from his position as Managing Director & Chief Executive Officer, with his resignation taking effect from the close of business hours on June 30, 2026. His departure will be followed by the appointment of Mr. Siddharth Mittal as Additional Director, designated as Managing Director & Chief Executive Officer.

Mr. Mittal's appointment includes designation as a Key Managerial Personnel and membership in the Executive Committee. His five-year term will commence on July 01, 2026, subject to shareholder approval. The company has confirmed that Mr. Mittal is not debarred from holding directorial positions by SEBI or any other regulatory authority.

Leadership Profiles and Experience

Ms. Kiran Mazumdar Shaw brings over four decades of biotechnology experience as the founder of Biocon Group, having led the organization since its inception in 1978. Under her leadership, Biocon has evolved into a global biopharmaceutical enterprise focused on innovation and affordable healthcare. She has received several national and international honors, including the Padma Shri and Padma Bhushan.

Mr. Siddharth Mittal joins from his role as Managing Director and CEO of Biocon Limited, bringing over two decades of experience in strategic finance, mergers and acquisitions, and general management. He initially joined Biocon in May 2013, serving as President & Chief Financial Officer until November 2019.

Strategic Impact and Business Focus

During his tenure at Biocon, Mr. Mittal contributed significantly to the growth of the biosimilars business and its transition into Biocon Biologics in 2019. Under his leadership, Biocon expanded into complex peptides and GLP-1 therapies, entering strategically significant segments in modern pharmaceuticals.

He also spearheaded the company's entry into the Generic Formulations segment, building a portfolio of over 20 products across global markets. These leadership changes represent a strategic transition for Syngene International as it continues to strengthen its position in the biotechnology services sector.